Evidence map›Paper›PMID 33665357›Full record

ArticleMolecular therapy oncolytics2021

IRGM promotes melanoma cell survival through autophagy and is a promising prognostic biomarker for clinical application.

Linlu Tian, Hongxue Meng, Xiao Dong, Xinlei Li, Zilin Shi, Hulun Li, Lie Zhang, Yue Yang, Ruijie Liu, Chunying Pei and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy oncolytics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Autophagy and Bacterial infections.Autophagy reports · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Role of HMGB1 in Cutaneous Melanoma: State of the Art.International journal of molecular sciences · 2022
    Review
  7. Immunity-related GTPase IRGM at the intersection of autophagy, inflammation, and tumorigenesis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Linlu TianDepartment of Immunology, Heilongjiang Provincial Key Laboratory for Infection and Immunity, Harbin Medical University, Harbin 150081, China.
Hongxue MengDepartment of Pathology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Xiao DongDepartment of Immunology, Heilongjiang Provincial Key Laboratory for Infection and Immunity, Harbin Medical University, Harbin 150081, China.
Xinlei LiDepartment of Anatomy, Harbin Medical University, Harbin 150081, China.
Zilin ShiDepartment of Immunology, Heilongjiang Provincial Key Laboratory for Infection and Immunity, Harbin Medical University, Harbin 150081, China.
Hulun LiDepartment of Neurobiology, Harbin Medical University, Harbin 150081, China.
Lie ZhangDepartment of Immunology, Heilongjiang Provincial Key Laboratory for Infection and Immunity, Harbin Medical University, Harbin 150081, China.
Yue YangDepartment of Immunology, Heilongjiang Provincial Key Laboratory for Infection and Immunity, Harbin Medical University, Harbin 150081, China.
Ruijie LiuDepartment of Immunology, Heilongjiang Provincial Key Laboratory for Infection and Immunity, Harbin Medical University, Harbin 150081, China.
Chunying PeiDepartment of Immunology, Heilongjiang Provincial Key Laboratory for Infection and Immunity, Harbin Medical University, Harbin 150081, China.
Bo LiDepartment of Immunology, Heilongjiang Provincial Key Laboratory for Infection and Immunity, Harbin Medical University, Harbin 150081, China.
Hongwei XuDepartment of Immunology, Heilongjiang Provincial Key Laboratory for Infection and Immunity, Harbin Medical University, Harbin 150081, China.
Rui LiDepartment of Neurology and Center for Neuroinflammation and Experimental Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA.
Harbin Medical University · CNUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previously, we showed that mouse immunity-related guanosine triphosphatase (GTPase) family M protein 1 (Irgm1) promotes malignant melanoma progression by inducing cellular autophagy flux and metastasis. Human IRGM, a truncated protein functionally distinct from its mouse counterpart, has several splice isoforms. In this study, we analyzed the association of IRGM and human melanoma clinical prognosis and investigated the function of IRGM in human melanoma cells. Data from the training cohort (n = 144) showed that overexpression of IRGM is proportional to melanoma genesis and clinical stages in human tissue chips. A validation cohort (n = 78) further confirmed that IRGM is an independent risk factor promoting melanoma progression and is associated with poor survival of patients. Among IRGM isoforms, we found that IRGMb is responsible for such correlation. In addition, IRGM promoted melanoma cell survival through autophagy, both

Indexed as

autophagyIRGMMelanomaprognostic biomaker

Identifiers

PMID33665357
PMCPMC7889451
OpenAlexW3116686474

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.